FDA to review MRI (magnetic resonance imaging) data analysis software:
This article was originally published in Clinica
Confirma says that the US FDA has accepted for review the second of a five-module PMA application for its software product that analyses MRI data to improve a doctor's ability to stage cancer patients. The ACCENT software analyses MRI data to provide information about the size and locations of cancerous tumours throughout the body. It is currently being tested in a clinical trial involving breast and prostate cancer patients, reports the Kirkland, Washington company.